Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have had type 2 diabetes (T2D) for ≥6 months according to the World Health Organization (WHO) classification.
Have HbA1c of 7.0% to 10.5%, inclusive, as assessed by the central laboratory.
If on metformin, have been treated with stable doses of metformin for at least 3 months.
Have a body mass index (BMI) ≥23 and \<50 kilograms per square meter.
You may not be if
Have type 1 diabetes (T1D).
Have used any glucose-lowering medication other than metformin within 3 months prior to study entry or during screening/lead-in period or have used any glucagon-like peptide-1 receptor agonists (GLP-1 RAs) at any time in the past.
Have had any of the following cardiovascular conditions: acute myocardial infarction (MI), New York Heart Association Class III or Class IV heart failure, or cerebrovascular accident (stroke).
Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine aminotransferase (ALT) level \>2.5 times the upper limit of the reference range, as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial.
Have had chronic or acute pancreatitis any time prior to study entry.
Have an estimated glomerular filtration rate (eGFR) \<45 milliliters/minute/1.73 square meter, calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation.
Have serum calcitonin ≥20 picograms per milliliter, as determined by the central laboratory at study entry.
Have any condition that is a contraindication for use of the GLP-1 RA class (per country-specific labels) at study entry or develop such condition between study entry and randomization.
